Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Drug common name | Zoliflodacin |
INN | zoliflodacin |
Description | Zoliflodacin (development codes AZD0914 and ETX0914) is an experimental antibiotic that is being studied for the treatment of infection with Neisseria gonorrhoeae (gonorrhea). It has a novel mechanism of action which involves inhibition of bacterial type II topoisomerases. Zoliflodacin is being developed by Innoviva Specialty Therapeutics, and the drug has demonstrated clinical efficacy equivalent to ceftriaxone in Phase III clinical trials.
|
Classification | Small molecule |
Drug class | antibiotics, DNA gyrase and topoisomerase IV inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1O[C@H](C)CN2c3c(cc4c(N5C(=O)OC[C@@H]5C)noc4c3F)CC3(C(=O)NC(=O)NC3=O)[C@@H]12 |
PDB | — |
CAS-ID | 1620458-09-4 |
RxCUI | — |
ChEMBL ID | CHEMBL3544978 |
ChEBI ID | — |
PubChem CID | 76685216 |
DrugBank | DB12817 |
UNII ID | FWL2263R77 (ChemIDplus, GSRS) |